ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Mapping the global research landscape of matrix metalloproteinase-12 (MMP-12) as a therapeutic target in pulmonary diseases: a bibliometric analysis (2000-2025).
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Matrix metalloproteinase-12 (MMP-12) is a macrophage-derived zinc-dependent endopeptidase that plays a critical role in extracellular matrix degradation, chronic inflammation, and tissue remodeling in pulmonary diseases. Increasing evidence has established MMP-12 as an important therapeutic target in chronic obstructive pulmonary disease (COPD), asthma, emphysema, pulmonary fibrosis, and other respiratory disorders. However, the global research landscape, scientific collaborations, and emerging trends in this field have not been comprehensively evaluated. This study aimed to characterize the evolution of MMP-12 research in pulmonary diseases using bibliometric analysis. Bibliographic records were retrieved from the Dimensions AI database, with metadata verification performed using Scopus, Web of Science Core Collection, and PubMed. The exported dataset was analyzed using Bibliometrix (Biblioshiny; R version 4.4.1) and VOSviewer (version 1.6.20) to evaluate annual scientific production, citation performance, collaboration networks, author and institutional productivity, Bradford's law, Lotka's law, keyword co-occurrence, and thematic evolution. A total of 2500 publications published between 2000 and 2025 were analyzed. Annual scientific production demonstrated a significant upward trend over the study period (β = 6.41 publications/year, R
Indexed as
Identifiers
42608560What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.